NCT05223088

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: a Single-arm, Prospective, Multicenter Trial (TAOS-3B-Trial)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.

Conditions

• Immunotherapy
• Gastrict Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
DRUG	Apatinib Mesylate	Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
DRUG	oxaliplatin	Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
DRUG	Tegafur	Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.

Timeline

• Start date: 2021-10-31
• Primary completion: 2023-04-30
• Completion: 2024-04-30
• First posted: 2022-02-03
• Last updated: 2025-03-18

Locations

1 site across 1 country: China